Xtant Medical Reports Q1 Revenue of $20.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy XTNT?
Reports Q1 revenue $20.9M vs. $32.9M last year. Sean Browne, President and CEO of Xtant Medical, stated, "The Q1 of 2026 and subsequent period were pivotal for Xtant. Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category. We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilon's 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond. These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XTNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XTNT
Wall Street analysts forecast XTNT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.470
Low
1.50
Averages
1.50
High
1.50
Current: 0.470
Low
1.50
Averages
1.50
High
1.50
About XTNT
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xtant Medical Holdings Raises 2026 Revenue Guidance Amid Strategic Expansion
- Revenue Guidance Increase: Xtant Medical has raised its full-year 2026 revenue guidance to between $101 million and $105 million, reflecting the addition of HEMOBLAST and growth in its core business, indicating strong expansion potential in the biologics market.
- Strategic Partnership Agreement: The exclusive U.S. distribution agreement with Dilon Technologies grants Xtant entry into an estimated $2 billion hemostatic product market, which is expected to significantly enhance market share and sales capabilities.
- Sales Team Expansion: The company plans to double the number of regional sales representatives in 2026 and has hired 21 sales professionals from Dilon to enhance market coverage and client responsiveness, further driving sales growth.
- Improved Financial Position: The total revenue for Q1 was $20.9 million with a gross margin of 57.3%, and although there was a net loss of $3.1 million, the $10.7 million received from divestitures will be used to reduce borrowings, strengthen cash flow, and optimize financial structure.
See More
Xtant Medical Reports Q1 Earnings and Raises FY26 Guidance
- Earnings Performance: Xtant Medical reported a Q1 GAAP EPS of -$0.02 with revenues of $20.9 million, reflecting a significant year-over-year decline of 36.5%, indicating pressure and challenges in the competitive landscape.
- Guidance Increase: The company raised its full-year 2026 revenue guidance to a range of $101 million to $105 million, surpassing the consensus estimate of $97.35 million, demonstrating management's confidence and positive outlook for future performance.
- Impact of Business Adjustments: With the divestiture of Companion Spine and the roll-off of Q-code licensing revenue, Xtant anticipates a revenue outlook of $95 million to $99 million for 2026, highlighting both challenges and opportunities in its strategic adjustments.
- Market Reaction: Although the Q1 results fell short of expectations, the company's better-than-expected full-year revenue guidance may help bolster investor confidence and potentially drive a rebound in stock price.
See More
Xtant Acquires Dilon Sales Team to Expand Market Reach
- Market Expansion Partnership: Xtant has secured exclusive U.S. distribution rights for Dilon's HEMOBLAST®Bellows, targeting the estimated $2 billion global hemostatic products market, which significantly enhances Xtant's market share and competitive positioning.
- Sales Team Integration: The integration of Dilon's approximately 20-person U.S. sales team into Xtant will bolster its commercial capabilities, enabling more effective responses to the needs of surgeons and patients, thereby driving sales growth.
- Distinct Product Advantages: HEMOBLAST is uniquely positioned as the only hemostatic product containing collagen and human-derived thrombin, applicable across various bleeding types, which is expected to attract more surgeons and solidify Xtant's leadership in the surgical hemostat market.
- Financial Guidance Update: Xtant plans to update its full-year 2026 financial guidance in conjunction with the release of its first quarter 2026 financial results, indicating a positive outlook for revenue growth stemming from the new distribution arrangement.
See More
Xtant Medical Holdings Reports Q4 2025 Earnings and Strategic Outlook
- Strong Financial Performance: Xtant Medical reported Q4 2025 revenue of $32.4 million, exceeding analysts' expectations of $30.75 million, despite losing approximately $2 million in revenue due to the Companion Spine divestiture, demonstrating resilience in its core biologics business.
- Successful Strategic Pivot: The final purchase price for Companion Spine was approximately $21.4 million, fully closed and settled, with proceeds used to reduce borrowings and strengthen cash flow, indicating a strategic shift towards focusing on high-margin biologics.
- Optimistic Growth Outlook: Management guided 2026 revenue to be between $95 million and $99 million, acknowledging challenges from divestitures and license revenue expirations, yet remains optimistic about organic growth in the core biologics business, expected to accelerate with new product launches.
- Enhanced Operational Efficiency: The company doubled the number of regional sales representatives in 2025 and plans to add resources to the national accounts team, aiming to drive revenue growth through increased commercial investment and further solidify its market position.
See More
Xtant Medical Q4 Earnings Beat Expectations with Revenue Growth
- Strong Earnings Report: Xtant Medical reported a Q4 GAAP EPS of $0.00, beating expectations by $0.01, with revenue of $32.36 million reflecting a 2.7% year-over-year increase, surpassing market expectations by $1.61 million, indicating stable performance in the market.
- Adjusted EBITDA Growth: The company's non-GAAP adjusted EBITDA for Q4 reached $1.9 million, a significant increase from $0.4 million in the prior year quarter, demonstrating notable improvements in cost control and operational efficiency.
- 2026 Financial Guidance: Xtant anticipates full-year 2026 revenue between $95 million and $99 million, below the consensus of $110.1 million, primarily driven by organic growth in its core higher-margin biologics business, but offset by the impact of asset sales.
- Strategic Adjustment Impact: This outlook reflects the anticipated effects of the December 2025 sale of non-core Coflex® and CoFix assets and international hardware businesses, as well as the cessation of license revenue related to Q-Code and amniotic membrane agreements, highlighting the company's strategic decision to optimize its business portfolio.
See More
Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft
- Product Innovation: Xtant Medical has launched nanOss Strata™, a synthetic bone graft made from hydroxycarbonapatite (HCA) with higher solubility than traditional materials, aimed at enhancing bioactivity and improving integration with surrounding bone tissue during healing.
- Market Availability: Strata™ is now accessible through Xtant Medical's nationwide distribution network, marking the company's ongoing commitment to innovation in regenerative medicine and aiming to assist surgeons in improving patient surgical outcomes.
- Diverse Product Forms: The product is available in compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and highly moldable, allowing for rapid absorption of blood and other biological fluids to meet various surgical needs.
- Strategic Goals: By introducing Strata™, Xtant Medical further solidifies its position in the orthopedic and spinal surgical solutions market, which is expected to drive future revenue growth and enhance market share.
See More
Xtant Medical Holdings Raises 2026 Revenue Guidance Amid Strategic Expansion
- Revenue Guidance Increase: Xtant Medical has raised its full-year 2026 revenue guidance to between $101 million and $105 million, reflecting the addition of HEMOBLAST and growth in its core business, indicating strong expansion potential in the biologics market.
- Strategic Partnership Agreement: The exclusive U.S. distribution agreement with Dilon Technologies grants Xtant entry into an estimated $2 billion hemostatic product market, which is expected to significantly enhance market share and sales capabilities.
- Sales Team Expansion: The company plans to double the number of regional sales representatives in 2026 and has hired 21 sales professionals from Dilon to enhance market coverage and client responsiveness, further driving sales growth.
- Improved Financial Position: The total revenue for Q1 was $20.9 million with a gross margin of 57.3%, and although there was a net loss of $3.1 million, the $10.7 million received from divestitures will be used to reduce borrowings, strengthen cash flow, and optimize financial structure.
See More
Xtant Medical Reports Q1 Earnings and Raises FY26 Guidance
- Earnings Performance: Xtant Medical reported a Q1 GAAP EPS of -$0.02 with revenues of $20.9 million, reflecting a significant year-over-year decline of 36.5%, indicating pressure and challenges in the competitive landscape.
- Guidance Increase: The company raised its full-year 2026 revenue guidance to a range of $101 million to $105 million, surpassing the consensus estimate of $97.35 million, demonstrating management's confidence and positive outlook for future performance.
- Impact of Business Adjustments: With the divestiture of Companion Spine and the roll-off of Q-code licensing revenue, Xtant anticipates a revenue outlook of $95 million to $99 million for 2026, highlighting both challenges and opportunities in its strategic adjustments.
- Market Reaction: Although the Q1 results fell short of expectations, the company's better-than-expected full-year revenue guidance may help bolster investor confidence and potentially drive a rebound in stock price.
See More
Xtant Acquires Dilon Sales Team to Expand Market Reach
- Market Expansion Partnership: Xtant has secured exclusive U.S. distribution rights for Dilon's HEMOBLAST®Bellows, targeting the estimated $2 billion global hemostatic products market, which significantly enhances Xtant's market share and competitive positioning.
- Sales Team Integration: The integration of Dilon's approximately 20-person U.S. sales team into Xtant will bolster its commercial capabilities, enabling more effective responses to the needs of surgeons and patients, thereby driving sales growth.
- Distinct Product Advantages: HEMOBLAST is uniquely positioned as the only hemostatic product containing collagen and human-derived thrombin, applicable across various bleeding types, which is expected to attract more surgeons and solidify Xtant's leadership in the surgical hemostat market.
- Financial Guidance Update: Xtant plans to update its full-year 2026 financial guidance in conjunction with the release of its first quarter 2026 financial results, indicating a positive outlook for revenue growth stemming from the new distribution arrangement.
See More
Xtant Medical Holdings Reports Q4 2025 Earnings and Strategic Outlook
- Strong Financial Performance: Xtant Medical reported Q4 2025 revenue of $32.4 million, exceeding analysts' expectations of $30.75 million, despite losing approximately $2 million in revenue due to the Companion Spine divestiture, demonstrating resilience in its core biologics business.
- Successful Strategic Pivot: The final purchase price for Companion Spine was approximately $21.4 million, fully closed and settled, with proceeds used to reduce borrowings and strengthen cash flow, indicating a strategic shift towards focusing on high-margin biologics.
- Optimistic Growth Outlook: Management guided 2026 revenue to be between $95 million and $99 million, acknowledging challenges from divestitures and license revenue expirations, yet remains optimistic about organic growth in the core biologics business, expected to accelerate with new product launches.
- Enhanced Operational Efficiency: The company doubled the number of regional sales representatives in 2025 and plans to add resources to the national accounts team, aiming to drive revenue growth through increased commercial investment and further solidify its market position.
See More
Xtant Medical Q4 Earnings Beat Expectations with Revenue Growth
- Strong Earnings Report: Xtant Medical reported a Q4 GAAP EPS of $0.00, beating expectations by $0.01, with revenue of $32.36 million reflecting a 2.7% year-over-year increase, surpassing market expectations by $1.61 million, indicating stable performance in the market.
- Adjusted EBITDA Growth: The company's non-GAAP adjusted EBITDA for Q4 reached $1.9 million, a significant increase from $0.4 million in the prior year quarter, demonstrating notable improvements in cost control and operational efficiency.
- 2026 Financial Guidance: Xtant anticipates full-year 2026 revenue between $95 million and $99 million, below the consensus of $110.1 million, primarily driven by organic growth in its core higher-margin biologics business, but offset by the impact of asset sales.
- Strategic Adjustment Impact: This outlook reflects the anticipated effects of the December 2025 sale of non-core Coflex® and CoFix assets and international hardware businesses, as well as the cessation of license revenue related to Q-Code and amniotic membrane agreements, highlighting the company's strategic decision to optimize its business portfolio.
See More
Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft
- Product Innovation: Xtant Medical has launched nanOss Strata™, a synthetic bone graft made from hydroxycarbonapatite (HCA) with higher solubility than traditional materials, aimed at enhancing bioactivity and improving integration with surrounding bone tissue during healing.
- Market Availability: Strata™ is now accessible through Xtant Medical's nationwide distribution network, marking the company's ongoing commitment to innovation in regenerative medicine and aiming to assist surgeons in improving patient surgical outcomes.
- Diverse Product Forms: The product is available in compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and highly moldable, allowing for rapid absorption of blood and other biological fluids to meet various surgical needs.
- Strategic Goals: By introducing Strata™, Xtant Medical further solidifies its position in the orthopedic and spinal surgical solutions market, which is expected to drive future revenue growth and enhance market share.
See More
